Log in

Poxel Stock Forecast, Price & News

0.00 (0.00 %)
(As of 10/30/2020 12:00 AM ET)
Today's Range
Now: $7.70
50-Day Range
MA: $7.75
52-Week Range
Now: $7.70
Average Volume10,026 shs
Market Capitalization$185.49 million
P/E RatioN/A
Dividend YieldN/A
Poxel S.A., a biopharmaceutical company, develops drugs for metabolic diseases with primary focus on type II diabetes. Its lead product is Imeglimin, an oral anti-diabetic candidate, which is in Phase III clinical development stage that targets the organs of diabetes, such as pancreas, liver, and muscles. The company is also developing PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in Phase IIa clinical trial that controls body energy metabolism and treats chronic metabolic diseases, such as non-alcoholic steatohepatitis (NASH). It has a licensing agreement with Enyo Pharma for the development of PXL007 (EYP001), an FXR agonist that is in Phase I study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in phase I clinical trials for the treatment of NASH. The company was founded in 2009 and is headquartered in Lyon, France.
Read More
Poxel logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.61 out of 5 stars

Industry, Sector and Symbol

Industry Private households



Sales & Book Value

Annual Sales$88.11 million
Cash Flow$0.65 per share
Book Value$2.68 per share



Market Cap$185.49 million
Next Earnings DateN/A
OptionableNot Optionable
0.00 (0.00 %)
(As of 10/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PXXLF News and Ratings via Email

Sign-up to receive the latest news and ratings for PXXLF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Poxel (OTCMKTS:PXXLF) Frequently Asked Questions

How has Poxel's stock price been impacted by COVID-19?

Poxel's stock was trading at $8.85 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PXXLF stock has decreased by 13.0% and is now trading at $7.70.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Poxel?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Poxel in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Poxel

Who are some of Poxel's key competitors?

Who are Poxel's key executives?

Poxel's management team includes the following people:
  • Mr. Thomas Kuhn M.B.A., Pharm.D., Pharm D MBA, Co-Founder, CEO & Director
  • Dr. Sébastien Bolze Ph.D., Pharm.D., Pharm D Ph.D., Co-Founder, COO & Exec. VP
  • Dr. Pascale Fouqueray-Grellier M.D., Ph.D., Co-Founder and Exec. VP of Clinical Devel. & Regulatory Affairs
  • Dr. Sophie Hallakou-Bozec Ph.D., Co-Founder and Sr. VP of R&D Pharmacology & Scientific Communication
  • Ms. Anne Renevot, Exec. VP & CFO

What is Poxel's stock symbol?

Poxel trades on the OTCMKTS under the ticker symbol "PXXLF."

How do I buy shares of Poxel?

Shares of PXXLF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Poxel's stock price today?

One share of PXXLF stock can currently be purchased for approximately $7.70.

How big of a company is Poxel?

Poxel has a market capitalization of $185.49 million and generates $88.11 million in revenue each year. Poxel employs 51 workers across the globe.

What is Poxel's official website?

The official website for Poxel is www.poxel.com.

How can I contact Poxel?

Poxel's mailing address is 259-261 Avenue Jean Jaures, Lyon I0, 69007. The company can be reached via phone at 33-4-37-37-20-10 or via email at [email protected]

This page was last updated on 10/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.